The United States Food and Drug Administration (US FDA) has flagged serious concerns at Dabur India’s manufacturing facility in Silvassa, Dadra and Nagar Haveli, following an inspection conducted in January 2026. The agency issued a Form 483 citation, documenting multiple deficiencies including risks of microbiological contamination, lapses in equipment cleaning and maintenance, and allegations that certain production records were falsified to conceal how machinery was being used.
Among the more striking observations, FDA inspectors reported finding a live bird and bird droppings inside a raw material warehouse located near packaging materials. Inspectors also noted that while official test records showed samples met safety limits, significant contamination was observed in multiple samples during the actual inspection — raising questions about the reliability of the plant’s in-house testing.
Dabur India has acknowledged the inspection and stated that the area where bird droppings were found is far from its active production zone. The company noted the plant primarily manufactures petroleum jelly for export, and that no product quality issues were identified.
Under FDA regulations, companies issued a Form 483 are required to submit corrective action plans. The regulator will assess whether Dabur’s response is adequate before determining further steps.
Written by : Arundhuti Chatterjee & Sharon Bose
Graphics by: Pramit Hazra
